{
  "docId": "019de076-1fa8-714d-830b-c99557c4e3f8",
  "docSlug": "94eecf41575130a8334503229ea21cd4",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 26,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "other",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines trial design cohorts (E, F, G, I, J, K) and summarizes findings from parts 1 & 2.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de076-1fa8-714d-830b-c99557c4e3f8/11",
  "deckHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8",
  "deckJsonHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8.json",
  "deckAnchorHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.33,
        "y": 0.17
      },
      "kind": "diagram",
      "text": "Part 3: Multiple Ascending Dose in cHBV Patients",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "916b5e4f-f925-47a5-bb42-450246a0c662",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.22,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Robust HBsAg declines across all cohorts; HBV DNA declines in HBV DNA+ patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc6df504-9dfd-4090-aae8-12f4c3a58473",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Part 1 & 2: Single-ascending dose",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e6acf0-b504-4b4e-9bb8-2a53740fc484",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.34,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "HBeAg: HBV E antigen | TDF: tenofovir disoproxil fumarate | Data presented at EASL 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ec993f5-4dda-4238-a627-64df6f205e9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "AB-729-001: Phase 1a/1b Clinical Trial with Imdusiran",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cc910fd-068e-4076-a4dc-fd8385adf8b3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "19535154-91e5-4e57-a1b7-3e1d7891f13d",
      "evidence": "emphasis on unmet medical need and treatment benefits",
      "position": 0,
      "objective": "highlight the need for HBV treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}